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ResistinAbstract Adipokines are factors produced by adipose tissue, that may be proinﬂammatory (such
as leptin and resistin) or anti-inﬂammatory (such as adiponectin). Effects of these adipokines on the
lungs have the potential to evoke or exacerbate asthma.
Aim: Our aim was to assess if serum resistin level is changed in obese and non obese asthmatic
children and if it can predict their responsiveness to inhaled glucocorticoids.
Methods: Serum levels of resistin, were measured in 60 asthmatic children (30 obese and 30 non
obese asthmatic children), and in 30 age and sex matched healthy controls. The measurements were
repeated in all asthmatics after 8 weeks of treatment with inhaled corticosteroids.
Results: Serum resistin levels were found to be signiﬁcantly elevated in all asthmatic children
than control group and it was signiﬁcantly elevated in obese children, compared with asthmatic
non obese and control children 35 ± 0.2 ng/mL vs 20 ± 0.25 vs 10 ± 0.11 ng/mL respectively
(F< 0.005). There was negative correlation between asthma severity as detected by FEV1 and
serum resistin levels. Serum resistin levels in all asthmatic children had no correlation with duration
of asthma in years. Serum resistin level was signiﬁcantly reduced in all asthmatic children after
inhaled corticosteroids for 8 weeks. Also asthmatic children with good response to inhaled corticos-
teroids had high initial resistin levels compared to corticosteroids non-responder.
Conclusions: From these results we can conclude that resistin can be considered as a marker of
asthma and its severity and high resistin levels can predict favourable anti-inﬂammatory effect of
inhaled glucocorticoids suggesting that resistin may be a marker of steroid-sensitive genotype in
asthma in children.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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2 H.M. Al-Asy, M.M. MabroukIntroduction
Asthma is a chronic inﬂammatory airway disease characterized
by cough, chest tightness and wheezing, and it is associated
with reversible or variable airway obstruction. However, the
diagnosis and follow-up of the disease are currently based on
symptoms and lung function measurements rather than on
assessing the underlying inﬂammatory process [1]. Several
asthma phenotypes with different inﬂammatory mechanisms
have been described suggesting that asthma is not a single dis-
ease entity but a syndrome with different underlying causes
and mechanisms [2]. Adipokines like leptin, adiponectin, resis-
tin and adipsin are protein mediators secreted by adipocytes
and macrophages within the adipose tissue [3]. Leptin and
resistin are usually pro-inﬂammatory, while adiponectin has
mainly anti-inﬂammatory properties [3]. There are some evi-
dence suggesting connections between adipokines and asthma.
However, further studies are needed to understand the role of
adipokines in the pathogenesis of, and more importantly, in
predicting treatment responses in different phenotypes of
asthma. The efﬁcacy of treatment with inhaled glucocorticoids
seems to vary between asthmatic phenotypes, and phenotype-
speciﬁc predictors of treatment response are needed [2]. The
aim of the present study was to assess serum levels of resistin
in obese and non obese asthmatic children and to assess if it
can predict the responsiveness to inhaled corticosteroids in
asthmatic children.
Subjects
Sixty asthmatic children (mean age 8 years, range 5–15 years)
diagnosed according to GINA guide lines and followed up in
asthma clinic in Pediatric department of Tanta University
Hospital were enrolled in this study Asthmatic children
were classiﬁed into 2 groups. Obese asthmatic children (group
1) and non obese asthmatics (group 2), in addition to
30 age and sex matched healthy children as control group
(group 3).
Exclusion criteria
Children with chronic heart or pulmonary or endocrine disease
and children who received inhaled glucocorticoids in the last
6 weeks before the study were excluded.Table 1 The demographic s of the studied groups.
Obese asthmatics
Age (Years)
Mean ± SD
8.25 ± 1.5
Sex
M 12
F 18
Duration of asthma (years) mean ± SD 5.5 ± 2.5
BMI
Mean ± SD
34.2 ± 2.1
Eosinophils (Cell/ml)
Mean ± SD
400 ± 20
IgE
Mean ± SD
280 ± 10
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All children were subjected to full history taking, thorough
clinical examination, BMI, pulmonary function test including
FEV1. Lung function, asthma symptom score, and serum levels
of resistin were measured in all asthmatics and in controls. The
asthmatics also ﬁlled in an asthma symptom questionnaire.
The same measurements were repeated in all asthmatic chil-
dren after 8 weeks of treatment with inhaled glucocorticoids
500 lg b.i.d. during weeks 1–4, and 250 lg b.i.d. during weeks
5–8). The study was approved by the ethics committee of
Tanta University Hospital and parents of all subjects gave
written informed consent.
Sample collection
Venous blood was collected for the assessment of serum levels
of resistin determined by enzyme-immuno-assay (EIA) by
using commercial reagents (DuoSet ELISA, R&D Systems
Europe Ltd, Abindgon, U.K. Netherlands) [4].
Asthma symptoms questionnaire
Asthma symptoms were recorded by using written symptom
questionnaire. Cough, chest tightness, wheezing and nocturnal
asthma symptoms were each scored from 0 to 3 yielding a total
score from 0 to 12 points [5].
Statistics
Differences in resistin levels between asthmatics and controls
were analysed with t-test, where appropriate. Pearson correla-
tion coefﬁcient was used to analyse correlations between resis-
tin levels and lung function indices. Changes in serum levels of
resistin before and after inhaled glucocorticoids treatment
were analysed with a paired t-test. Results were presented as
mean ± SD, and P-value <0.05 was considered as signiﬁcant.
SPSS 15.0.1 software
Results
The data base of all groups is given in Table 1. There were no
statistical signiﬁcant differences as regards age, sex percentages
between all asthmatics and controls. BMI was statistically sig-Non-obese asthmatics Controls F Value
8.20 ± 1.5 8.3 ± 1.25 F> 0.5
12 12 F> 0.5
18 18
5.00 ± 2.00 – F> 0.5
22 ± 1.1 22 ± 1.4 F< 0.05
380 ± 40 80 ± 10 F< 0.05
270 ± 15 50 ± 15 F< 0.05
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Table 2 Serum resistin levels in obese asthmatic and non-obese asthmatic children and controls.
Obese asthmatics Non-obese asthmatics Controls F value
Serum Resistin (ng/ml) mean ± SD 35 ± 0.2 20 ± 0.25 10 ± 0.11 F< 0.05
P< 0.05
Serum resistin as an asthma marker and predictor of inhaled corticosteroid response in bronchial asthma in children 3niﬁcantly higher in obese asthmatics than non obese asthmat-
ics and controls (34.2± 2.1 vs 22± 1.1 vs 22± 1.4 F< 0.05)
respectively. All asthmatic children obese and non-obese had
signiﬁcantly higher serum levels IgE and higher blood eosino-
phil count than controls (280± 10 vs 270± 15 vs 50± 15
respectively F< 0.05 and 400 vs 380± 40 vs± 10 respec-
tively F< 0.05), but there was no statistical differences
between obese asthmatics and non-obese asthmatics as regards
serum IgE levels or peripheral blood eosinophils. Obese asth-
matics had signiﬁcantly higher serum levels of resistin than
non obese asthmatics than controls (35± 0.2 vs 20± 0.25
vs 10± 0.11 respectively F< 0.05) as in Table 2. Serum resis-
tin showed a negative correlation with asthma severity as evi-
denced by FEV1 as seen in Fig. 1. No correlation was found
between serum levels of resistin and duration of asthma among
all asthmatic children as in Table 3.
Serum levels of resistin were signiﬁcantly reduced in all
asthmatic children after corticosteroid therapy for 8 weeks as
in Table 4. Twenty asthmatic children had relatively higher ini-
tial levels of serum resistin and 40 asthmatic children had rel-
atively less higher initial level of serum resistin (42± 2.1 vs 28
± 2.6 respectively P< 0.05) as in Table 5. Asthmatic children
either obese or non-obese with initial higher levels of resistin
showed signiﬁcant response to inhaled corticosteroids for eight
weeks than asthmatics with relatively low high resistin levels as
evidenced by marked reduction of their asthma questionerFigure 1 The correlation between serum resistin levels and
FEV1.
Table 3 Correlation between duration of asthma in asthmatic
children (in years) and mean serum resistin levels.
Duration of
asthma in all
asthmatics
(years)
Mean serum resistin
in all asthmatics
(obese and non obese)
P value
Mean SD 35 ± 0.2 27.7 ± 0.25 P> 0.05
Correlation
coeﬃcient
(r)
2.55
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with relatively less higher initial levels of serum resistin as in
Table 6.
Discussion
Asthma is often considered as a single disease entity, but it is
actually a syndrome with many different pathological path-
ways ultimately leading to quite similar clinical presentation
of variable airway obstruction with chest tightness, wheezing
and cough [1]. The role of adipokines varies between these dif-
ferent inﬂammatory processes. Resistin is associated with dif-
ferent inﬂammatory states [3] but there are only a few
previous publications on resistin in children with asthma [5].
Nuclear factor jB (NF-jB) is a transcription factor inducing
the expression of many pro-inﬂammatory adipokines [6].
Inhaled glucocorticoids is a corner stone in treatment of
asthma. Inhaled glucocorticoids exert their anti-inﬂammatory
effects through a wide variety of mechanisms, of which inhibi-
tion of NF-jB is one of the most important mechanism [7]. In
the present study, we investigated the serum resistin in obese
and non-obese asthmatic children. Our results showed that
mean resistin level was signiﬁcantly higher in all asthmatic chil-
dren (obese and non-obese) compared with control group. and
resistin levels were signiﬁcantly higher in obese asthmatic chil-
dren than non obese asthmatics. Also there was a negative cor-
relation between mean resistin levels and asthma severity. This
relation may be explained by the ﬁnding that resistin is an
endogenous agonist of Toll-like receptor 4 (TLR4) which leads
to activation of various genes involved in asthmatic inﬂamma-Table 4 The serum levels of resistin before and after
corticosteroid therapy.
Obese
asthmatics
Non-obese
asthmatics
P value of
paired T test
Initial serum resistin
before treatment
35 ± 0.2 20 ± 0.25 P< 0.05
Serum resistin after
corticosteroid therapy
15. ± 1.1 12. ± 1.2 P< 0.05
Table 5 Patients with initial higher levels of resistin.
Asthmatic children
with relatively
more higher initial
levels of resistin
Asthmatic children
with relatively less l
higher initial levels
of resistin
P value
Number of
patients
20 40
Serum
resistin
(ng/ml)
42 ± 2.1 28 ± 2.6 P< 0.05
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Table 6 Mean asthma questioner score in asthmatic children
with initial higher levels of serum resistin and asthmatic
children with les higher serum resistin levels before and after
inhaled corticosteroids.
Asthmatic children
with initial more
higher resistin levels
(no = 20)
Asthmatic children
with initial less higher
resistin levels
(no = 40)
Serum resistin 42 ± 2.1 28 2 ± .6
Mean asthma
questioner score
before
treatment
12 12
Mean asthma
questioner score
treatment after
1 5
4 H.M. Al-Asy, M.M. Mabrouktion through NF-kB pathway [8]. Our results are coincident
with the ﬁnding of LaRochelle et al. who showed that patients
with moderate to severe asthma had higher levels of resistin
than controls, and resistin levels were increased with increasing
disease severity [9]. On the contrary, Kim and colleagues found
that resistin levels were lower in atopic asthmatics than in
healthy controls, and resistin was associated with lower mark-
ers of atopy or bronchial responsiveness [10]. However, Arshi
et al. did not ﬁnd any differences in resistin levels between
patients with asthma and healthy controls [5]. Conﬂicting
results are likely to be explained by differences in patient
selection.
Our results showed also high pre-treatment resistin levels
were associated with a more pronounced improvement of
symptoms in asthmatic children after inhaled corticosteroids
treatment indicating a better steroid-response. This can be
explained by the fact that resistin may be able to enhance
the production of proinﬂammatory cytokines IL-6 and TNF-
a in human macrophages and this effect may be inhibited with
inhaled corticosteroids. Also, the expression of resistin itself
has been reported to be enhanced by inﬂammatory factors like
IL-1, IL-6, TNF-a and LPS by an NF-jB dependent manner
[11,12]. Therefore high resistin levels may reﬂect an asthmatic
phenotype characterized by increased NF-jB activity and
hence favourable response to glucocorticoids, the anti-
inﬂammatory action of which is primarily based on their sup-
pressive effect on NF-jB [12].
Conclusion
High resistin levels were present in obese and non obese asth-
matic children and were correlated with asthma severity sug-
gesting that the link between adipokine resistin and asthma
is not restricted to obesity, and resistin can be considered as
a marker of asthma and asthma severity. Also higher resistin
levels predicted favourable anti-inﬂammatory effect of inhaled
glucocorticoids suggesting that resistin may be a feature and
biomarker of steroid-sensitive phenotype of asthma.
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